We are live on ! Find out more
SPPI

Spectrum Pharmaceuticals

Delisted

SPPI was delisted on the 31st of July, 2023.

124 hedge funds and large institutions have $416M invested in Spectrum Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 42 increasing their positions, 46 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

425% more call options, than puts

Call options by funds: $677K | Put options by funds: $129K

38% more capital inflows, than outflows

Capital inflows: $35.2M | Capital outflows: $25.6M

1.68% more ownership

Funds ownership: 67.78% → 69.46% (+1.7%)

9% less repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 46

3% less funds holding

Funds holding: 128 → 124 (-4)

25% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 16

Holders
124
Holders Change
-4
Holders Change %
-3.13%
% of All Funds
3.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
42
Reduced
46
Closed
16
Calls
$677​K
Puts
$129​K
Net Calls
+$548​K
Net Calls Change
+$222​K

SPPI Hedge Fund Activity: Q2 2017 in Review

124 of the 4,024 institutional investors tracked by Wall St. Rank reported a position in Spectrum Pharmaceuticals (SPPI) for Q2 2017, worth a combined $416M — up 18% from $354M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of SPPI and 12 opened new positions — a net loss of 4 holders — while 46 trimmed existing stakes and 42 added.

The largest buyer was Consonance Capital Management, opening a new position worth an estimated $13.2M. The largest seller was Acadian Asset Management, exiting entirely with an estimated $4.31M sold.

  • 124 institutional investors held Spectrum Pharmaceuticals (SPPI) as of Q2 2017, down from 128 in Q1 2017.
  • Funds reported $416M of Spectrum Pharmaceuticals stock for Q2 2017, up 18% quarter-over-quarter.
  • 12 funds opened new Spectrum Pharmaceuticals positions in Q2 2017 and 16 closed out, a net change of -4 holders.
  • The largest Spectrum Pharmaceuticals buyer in Q2 2017 was Consonance Capital Management, an estimated $13.2M added.
  • The largest Spectrum Pharmaceuticals seller in Q2 2017 was Acadian Asset Management, an estimated $4.31M sold.

Based on aggregated 13F filings for Q2 2017.